Latest Breaking News On - Palleon pharmaceuticals - Page 6 : comparemela.com

Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - Palleon receives upfront payment and is eligible for up to $196.5 million in milestone payments - SHANGHAI, June 28, 2022 /PRNewswire/ Palleon Pharmaceuticals Inc., a companypioneering the field of glyco-immunology to treat cancer and inflammatory diseases, todayannounced a strategic collaboration with Shanghai Henlius Biotech, Inc. (2696.HK) to develop andcommercialize two bifunctional sialidase programs from Palleon's EAGLE (Enzyme-AntibodyGlyco-Ligand Editing) immuno-oncology platform, including Palleon's Bifunctional HER2-Sialidasenow in preclinical development and a second bifunctional sialidase to be developed with aproprietary target provided by Henlius. Palleon's EAGLE platform potentiates antitumor im

Hong kongWenjie zhangJim broderickShanghai henlius biotech incPalleon pharmaceuticals incPalleon pharmaceuticalsShanghai henlius biotechGlyco ligand editingChief executive officerExecutive directorNew drug applicationsGood manufacturingXuhui plantSongjiang first plantPalleon and henlius to co develop bifunctional her2 sialidase anda second be jointly designed received exclusive license for two products in china including hong kongNd taiwan palleon retains all other global rights receives upfront payment and is eligible for up to 196 5 million in milestone payments shanghai